-
1 month ago | 
oncpracticemanagement.com | Patricia A. Stewart |Phoebe Starr |Wayne Kuznar |Cecile Miller
The landscape of cancer and immunology has gone through major scientific advances in research over the past 2 decades. The emergence of immunotherapy as a treatment option for patients diagnosed with cancer has led to improvements in patient outcomes. Patients diagnosed with certain forms of cancer can now live longer and enjoy good quality of life.
-
Jan 15, 2025 | 
oncpracticemanagement.com | Wayne Kuznar |Patricia A. Stewart
Subgroup analyses presented at the American Society of Hematology (ASH) Annual Meeting San Diego support the clinical benefit of brentuximab vedotin (Adcetris; Pfizer) in heavily pretreated patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
-
Jun 26, 2024 | 
oncpracticemanagement.com | Patricia A. Stewart |Meg Barbor |Colleen Hall
BOSTON—Imagine a circle, with health care providers, researchers, and community partners such as churches making up the outer ring. In the center, picture a patient with cancer. All of those groups working together is the key to boosting clinical trial engagement, particularly in underrepresented populations, according to a panel of speakers at NCODA’s 6th Annual Oncology Institute meeting held here this week.
-
May 24, 2024 | 
theoncologynurse.com | Patricia A. Stewart
Patients undergoing hematopoietic stem-cell transplantation (HSCT) do not derive any benefit from the restrictive diet frequently prescribed to prevent infections, according to the results of a clinical trial presented during the 64th American Society of Hematology Annual Meeting and Exposition.
-
Oct 16, 2023 | 
theoncologynurse.com | Patricia A. Stewart
Chicago, IL—It is well documented that clinical trials thus far have for the most part excluded underserved populations, and that means the results of these trials cannot be generalized to society at large. Fortunately, the federal government and medical societies have taken aim at remedying this imbalance in accrual for clinical trials.
-
Aug 23, 2023 | 
oncpracticemanagement.com | Patricia A. Stewart |Meg Barbor
Crystal S. Denlinger, MD, FACP, has been named the new Chief Executive Officer (CEO) of the National Comprehensive Cancer Network (NCCN). She will succeed Robert W. Carlson, MD, who is retiring after more than 10 years leading the global guidelines organization. Dr Denlinger will assume her new role with NCCN on October 9, 2023.
—Crystal S. Denlinger, MD, FACP
—Crystal S.
-
Aug 11, 2023 | 
theoncologynurse.com | Patricia A. Stewart
According to findings from a phase 3 trial presented at the American Society for Radiation Oncology Annual Meeting 2022, the addition of stereotactic body radiation therapy (SBRT) to sorafenib (Nexavar) can lengthen overall survival (OS) and delay tumor progression in patients with unresectable advanced hepatocellular cancer (HCC) without compromising quality of life.
-
Aug 11, 2023 | 
theoncologynurse.com | Patricia A. Stewart
New results from the PATHFINDER clinical trial suggest that a multicancer early detection blood test can accurately identify the presence of cancer in apparently healthy people. The test, known as Galleri (developed by GRAIL), uses cell-free DNA and machine learning to detect a common cancer signal across more than 50 cancer types as well as to predict cancer signal origin. Once the test is validated and refined further, it may revolutionize the way in which cancer is diagnosed and treated.
-
Jul 17, 2023 | 
theoncologypharmacist.com | Patricia A. Stewart
Chicago, IL—The presidential theme for the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting was “Partnering With Patients: The Cornerstone of Clinical Care and Research.” In his address during the opening session of the meeting, Eric P. Winer, MD, FASCO, Director, Yale Cancer Center, and Physician-in-Chief, Smilow Cancer Hospital at Yale New Haven, CT, and ASCO’s 2022-2023 President, discussed the importance of physician–patient partnerships for improving healthcare outcomes.
-
Jul 11, 2023 | 
theoncologypharmacist.com | Patricia A. Stewart
During the 2023 American Association for Cancer Research Annual Meeting, researchers presented results from a phase 2b clinical trial demonstrating significant improvement in recurrence-free survival (RFS) in patients with high-risk melanoma who were treated with a combination of an investigational personalized mRNA-based vaccine plus the immune checkpoint inhibitor pembrolizumab (Keytruda), compared with pembrolizumab alone.1 “For the first time in a randomized study with a control arm, the...
